Comment le mode de vie influence-t-il le risque d'hypotension ?
Un mode de vie sédentaire, une mauvaise alimentation et le tabagisme augmentent le risque d'hypotension.
Mode de vieSédentaritéTabagisme
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Métaraminol : Questions médicales les plus fréquentes",
"headline": "Métaraminol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Métaraminol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-14",
"dateModified": "2026-08-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Métaraminol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phénylpropanolamine",
"url": "https://questionsmedicales.fr/mesh/D010665",
"about": {
"@type": "MedicalCondition",
"name": "Phénylpropanolamine",
"code": {
"@type": "MedicalCode",
"code": "D010665",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.092.063.624.706"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Métaraminol",
"alternateName": "Metaraminol",
"code": {
"@type": "MedicalCode",
"code": "D008680",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Arwa Abu Sardaneh",
"url": "https://questionsmedicales.fr/author/Arwa%20Abu%20Sardaneh",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia."
}
},
{
"@type": "Person",
"name": "Jonathan Penm",
"url": "https://questionsmedicales.fr/author/Jonathan%20Penm",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia."
}
},
{
"@type": "Person",
"name": "Matthew Oliver",
"url": "https://questionsmedicales.fr/author/Matthew%20Oliver",
"affiliation": {
"@type": "Organization",
"name": "Department of Emergency Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia."
}
},
{
"@type": "Person",
"name": "David Gattas",
"url": "https://questionsmedicales.fr/author/David%20Gattas",
"affiliation": {
"@type": "Organization",
"name": "School of Medicine, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia."
}
},
{
"@type": "Person",
"name": "Andrew J McLachlan",
"url": "https://questionsmedicales.fr/author/Andrew%20J%20McLachlan",
"affiliation": {
"@type": "Organization",
"name": "School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Dose equivalence for metaraminol and noradrenaline - A retrospective analysis.",
"datePublished": "2024-Apr-00",
"url": "https://questionsmedicales.fr/article/38245376",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jcrc.2023.154430"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of Weight-Adjusted Phenylephrine, Norepinephrine, and Metaraminol for Elective Cesarean Delivery on Neonatal Acid-Base Status: A Randomized Controlled Trial.",
"datePublished": "2022-09-21",
"url": "https://questionsmedicales.fr/article/36172051",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/DDDT.S381048"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of metaraminol versus no metaraminol on time to resolution of shock in critically ill patients.",
"datePublished": "2021-10-07",
"url": "https://questionsmedicales.fr/article/34620686",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/ejhpharm-2021-003035"
}
},
{
"@type": "ScholarlyArticle",
"name": "Kinetic and mechanism study of the spontaneous, solvent- and base-catalyzed degradation of the precursor of the β-nitro alcohol metaraminol by combining HPLC/electronic circular dichroism/theoretical methods.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35961211",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jpba.2022.114972"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dose equivalence between metaraminol and norepinephrine in critical care.",
"datePublished": "2021-07-13",
"url": "https://questionsmedicales.fr/article/34197654",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bcp.14969"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Amines",
"item": "https://questionsmedicales.fr/mesh/D000588"
},
{
"@type": "ListItem",
"position": 4,
"name": "Aminoalcools",
"item": "https://questionsmedicales.fr/mesh/D000605"
},
{
"@type": "ListItem",
"position": 5,
"name": "Propanolamines",
"item": "https://questionsmedicales.fr/mesh/D011412"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phénylpropanolamine",
"item": "https://questionsmedicales.fr/mesh/D010665"
},
{
"@type": "ListItem",
"position": 7,
"name": "Métaraminol",
"item": "https://questionsmedicales.fr/mesh/D008680"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Métaraminol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Métaraminol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-09-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Métaraminol",
"description": "Comment diagnostiquer une hypotension nécessitant du métaraminol ?\nQuels tests sont utilisés pour évaluer l'efficacité du métaraminol ?\nQuels signes cliniques indiquent un besoin de métaraminol ?\nComment évaluer la réponse au traitement par métaraminol ?\nQuels critères cliniques justifient l'utilisation du métaraminol ?",
"url": "https://questionsmedicales.fr/mesh/D008680#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Métaraminol",
"description": "Quels symptômes indiquent une hypotension ?\nQuels effets secondaires peuvent survenir avec le métaraminol ?\nComment reconnaître une réaction indésirable au métaraminol ?\nQuels symptômes nécessitent une attention médicale urgente ?\nQuels signes indiquent une surdose de métaraminol ?",
"url": "https://questionsmedicales.fr/mesh/D008680#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Métaraminol",
"description": "Comment prévenir l'hypotension lors d'une intervention chirurgicale ?\nQuelles mesures préventives pour les patients à risque ?\nComment éviter les effets secondaires du métaraminol ?\nQuels conseils pour les patients sous métaraminol ?\nComment gérer les interactions médicamenteuses avec le métaraminol ?",
"url": "https://questionsmedicales.fr/mesh/D008680#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Métaraminol",
"description": "Comment le métaraminol est-il administré ?\nQuelles sont les alternatives au métaraminol ?\nQuelle est la posologie standard du métaraminol ?\nComment surveiller l'efficacité du traitement par métaraminol ?\nQuels sont les protocoles de sevrage du métaraminol ?",
"url": "https://questionsmedicales.fr/mesh/D008680#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Métaraminol",
"description": "Quelles complications peuvent survenir avec le métaraminol ?\nComment gérer une hypertension induite par le métaraminol ?\nQuels sont les risques d'une surdose de métaraminol ?\nComment prévenir les complications liées au métaraminol ?\nQuels signes indiquent une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D008680#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Métaraminol",
"description": "Quels facteurs augmentent le risque d'hypotension ?\nComment l'âge influence-t-il le risque d'hypotension ?\nQuels médicaments augmentent le risque d'effets secondaires du métaraminol ?\nQuels antécédents médicaux sont des facteurs de risque ?\nComment le mode de vie influence-t-il le risque d'hypotension ?",
"url": "https://questionsmedicales.fr/mesh/D008680#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une hypotension nécessitant du métaraminol ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypotension est diagnostiquée par la mesure de la pression artérielle et l'évaluation clinique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité du métaraminol ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de pression artérielle et des évaluations hémodynamiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un besoin de métaraminol ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des étourdissements, une faiblesse ou un choc hypovolémique peuvent indiquer un besoin."
}
},
{
"@type": "Question",
"name": "Comment évaluer la réponse au traitement par métaraminol ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réponse est évaluée par la surveillance de la pression artérielle et des signes vitaux."
}
},
{
"@type": "Question",
"name": "Quels critères cliniques justifient l'utilisation du métaraminol ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation est justifiée par une hypotension persistante malgré d'autres traitements."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une hypotension ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des vertiges, des évanouissements, et une confusion mentale."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir avec le métaraminol ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent hypertension, tachycardie et maux de tête."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction indésirable au métaraminol ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réaction indésirable peut se manifester par des palpitations ou des douleurs thoraciques."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent une attention médicale urgente ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme une douleur thoracique sévère ou des difficultés respiratoires nécessitent une attention immédiate."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une surdose de métaraminol ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes de surdose incluent hypertension sévère, anxiété et tremblements."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hypotension lors d'une intervention chirurgicale ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne hydratation et une surveillance continue de la pression artérielle sont essentielles."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives pour les patients à risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients à risque doivent être surveillés étroitement et recevoir des fluides intraveineux si nécessaire."
}
},
{
"@type": "Question",
"name": "Comment éviter les effets secondaires du métaraminol ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pour éviter les effets secondaires, la posologie doit être ajustée et surveillée régulièrement."
}
},
{
"@type": "Question",
"name": "Quels conseils pour les patients sous métaraminol ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients doivent être informés des signes d'hypotension et des effets secondaires potentiels."
}
},
{
"@type": "Question",
"name": "Comment gérer les interactions médicamenteuses avec le métaraminol ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial d'évaluer toutes les médications du patient pour éviter des interactions dangereuses."
}
},
{
"@type": "Question",
"name": "Comment le métaraminol est-il administré ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le métaraminol est généralement administré par voie intraveineuse sous surveillance médicale."
}
},
{
"@type": "Question",
"name": "Quelles sont les alternatives au métaraminol ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les alternatives incluent la dopamine et la noradrénaline, selon la situation clinique."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie standard du métaraminol ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie standard varie, mais commence souvent à 0,5 à 1 mg par voie IV, ajustée selon la réponse."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement par métaraminol ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est surveillée par la pression artérielle et les signes vitaux du patient."
}
},
{
"@type": "Question",
"name": "Quels sont les protocoles de sevrage du métaraminol ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le sevrage doit être progressif pour éviter une hypotension rebond, sous surveillance médicale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le métaraminol ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des arythmies cardiaques, une hypertension sévère et des lésions tissulaires."
}
},
{
"@type": "Question",
"name": "Comment gérer une hypertension induite par le métaraminol ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension induite peut être gérée par l'ajustement de la posologie et l'administration d'antihypertenseurs."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une surdose de métaraminol ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surdose peut entraîner des complications graves comme des AVC ou des crises cardiaques."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées au métaraminol ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une surveillance étroite et un ajustement rapide de la posologie."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques, des troubles de la vision ou des convulsions nécessitent une attention immédiate."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hypotension ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la déshydratation, les maladies cardiaques et certains médicaments."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque d'hypotension ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées sont plus susceptibles de développer une hypotension en raison de la fragilité vasculaire."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le risque d'effets secondaires du métaraminol ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antidépresseurs et les antihypertenseurs peuvent augmenter le risque d'effets secondaires."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont des facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de maladies cardiovasculaires ou d'accidents vasculaires cérébraux sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il le risque d'hypotension ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire, une mauvaise alimentation et le tabagisme augmentent le risque d'hypotension."
}
}
]
}
]
}
Department of Intensive Care, Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia; Department of Critical Care, Department of Medicine, the University of Melbourne, Parkville, Victoria, Australia. Electronic address: rahul.costa-pinto@austin.org.au.
Department of Intensive Care, Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia; Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Department of Intensive Care, Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia; Data Analytics Research and Evaluation Centre, The University of Melbourne and Austin Hospital, Melbourne, Australia.
Department of Intensive Care, Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia; Department of Critical Care, Department of Medicine, the University of Melbourne, Parkville, Victoria, Australia; Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Department of Intensive Care, The Alfred Hospital, 55 Commercial Road, Melbourne, Victoria, Australia.
Department of Intensive Care, Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia; Department of Critical Care, Department of Medicine, the University of Melbourne, Parkville, Victoria, Australia.
Department of Intensive Care, Austin Hospital, 145 Studley Road, Heidelberg, Victoria, Australia; Department of Critical Care, Department of Medicine, the University of Melbourne, Parkville, Victoria, Australia; Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Data Analytics Research and Evaluation Centre, The University of Melbourne and Austin Hospital, Melbourne, Australia; Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Noradrenaline and metaraminol are commonly used vasopressors in critically ill patients. However, little is known of their dose equivalence....
We conducted a single centre retrospective cohort study of all ICU patients who transitioned from metaraminol to noradrenaline infusions between August 26, 2016 and December 31, 2020. Patients receivi...
We studied 195 patients. The median conversion ratio of metaraminol to noradrenaline was 12.5:1 (IQR 7.5-20.0) for the overall cohort. However, the coefficient of variation was 77% and standard deviat...
The median dose equivalence for metaraminol and noradrenaline in this study was 12.5:1. However, there was significant variance in dose equivalence, only half the proportion of variation in noradrenal...
Many previous trials have compared the effects of different vasoactive drugs on cesarean section patients, but their infusion rate is based on experience rather than high-quality evidence. It is diffi...
Women undergoing elective caesarean delivery under combined spinal-epidural anaesthesia were randomized to receive phenylephrine or norepinephrine or metaraminol infusion at the rate that was assumed ...
78 patients were included. The umbilical artery pH was not significantly different among the three groups (phenylephrine group: 7.33 ± 0.03 vs norepinephrine group: 7.33 ± 0.04 vs metaraminol group: 7...
Phenylephrine (0.54 μg/kg/min) or metaraminol (2 μg/kg/min) or norepinephrine (0.08 μg/kg/min) administered to healthy patients with elective cesarean section after spinal anesthesia has no significan...
There is limited evidence to support metaraminol use in critically ill patients. Metaraminol is not included as a vasopressor choice in international guidelines for the management of shock. Neverthele...
A single-centre retrospective matched observational study was conducted in a 54-bed intensive care unit of a tertiary hospital. Patients aged 16 years or older who were admitted from 2017 to 2019 with...
There were 286 patients included in this study, including 143 patients in each group. The median time to resolution of shock was 44 hours (IQR 28-66 hours) in the MET-NOR group compared with 27 hours ...
In critically ill patients, metaraminol may be associated with a longer time to resolution of shock compared with those who do not receive metaraminol....
Chiral β-nitro alcohols are key intermediates in the synthesis of a wide range of active pharmaceutical ingredients. Despite their massive use for pharmaceutical applications, in-depth kinetics studie...
The aim of this study was to determine the conversion dose ratio between continuous infusion metaraminol and norepinephrine in critically ill patients with shock....
A retrospective cohort study was conducted in adult patients with shock admitted to an intensive care unit from 29 October 2018 to 30 October 2019 and who transitioned from metaraminol monotherapy to ...
A total of 43 out of 144 eligible patients were included. The median age was 68 years (IQR 56-76) and 22 (51%) were male. There was no significant difference between the baseline MAP during metaramino...
A conversion dose ratio of 10:1 (metaraminol μg.kg...
A direct comparison of phenylephrine, metaraminol, and norepinephrine in preventing hypotension during spinal anaesthesia for elective caesarean section has never been made....
Seventy-five parturients scheduled for elective caesarean section were randomly assigned into the three groups. After spinal anaesthesia induction, patients received a bonus dose of vasopressor (norep...
The UA pH was 7.32±0.03 for metaraminol, 7.31±0.03 for phenylephrine, and 7.31±0.03 for norepinephrine. The 95% CI of MD was -0.011 to 0.026 comparing metaraminol with norepinephrine and 0.0181 to 0.0...
Both metaraminol and phenylephrine were non-inferior to norepinephrine with respect to neonatal UA pH when used as a bolus and continuous infusion to prevent hypotension during combined spinal-epidura...
Metaraminol is increasingly used as a vasopressor in critically ill patients. Nevertheless, there remains limited evidence to support its use in international guidelines for management of shock....
The aim of the study was to describe the pharmacoepidemiology of metaraminol in critically ill patients with shock....
A retrospective observational study was conducted in an intensive care unit (ICU) in Sydney, Australia. Patients admitted during a 1-year time frame who received metaraminol intravenous infusions for ...
A total of 152 patients were included. When metaraminol was used, it was the most common first-line vasopressor started for management of shock (97%, n = 147) and was used as monotherapy in 53% (n = 8...
Metaraminol is often administered as a first-line peripheral vasopressor in the ICU and is used as a single agent in patients with lower severity of shock....
To compare the effects of metaraminol and norepinephrine on hemodynamics and kidney injury in the treatment of septic shock, and calculate the conversion dose ratio between the two vasopressors....
This randomized controlled study was performed on 15 Guizhou miniature pigs. Septic shock was induced by fecal peritonitis in 10 animals, and 5 were used as a sham-operated group (shams). Fluid resusc...
There was no significant difference in MAP, heart rate, cardiac output (CO) and central venous pressure (CVP) between the two groups after treatment. No arrhythmias such as atrial fibrillation and ven...
Metaraminol has a similar pressor effect to norepinephrine in septic shock; it does not increase heart rate and aggravate kidney injury after shock compared with norepinephrine. And our research may p...
Metaraminol is a sympathomimetic amine vasopressor that can be administrated through a peripheral venous access. However, limited evidence restricts its application in critically ill patients. This st...
Patients who received peripheral metaraminol infusion between May 2019 and April 2022 were recruited. Data on baseline characteristics, clinical parameters, and infusion-related complications were ret...
273 patients who received metaraminol were enrolled. Of these, 35 (12.8%) patients required central venous catheter insertion due to inability in achieving hemodynamic stability following peripheral m...
Metaraminol could provide hemodynamic support and avoid complications associated with a central venous catheter and delay in vasopressor administration. Through careful and close monitoring, periphera...
The primary objective was to determine the proportion of hospitals that administered norepinephrine peripheral vasopressor infusions (PVIs) in critically ill adult patients. Secondary objectives were ...
An international multi-centre cross-sectional survey study was conducted in adult intensive care units in Australia, US, UK, Canada, and Saudi Arabia....
Critical care pharmacists from 132 institutions responded to the survey. Norepinephrine PVIs were utilised in 86% of institutions (n = 113/132). The median maximum duration of norepinephrine PVIs was ...
There is variability in clinical practice regarding PVI administration in critically ill adult patients dependent on drug availability and local institutional recommendations....